Association of COVID-19 and Cancer: Risk Statistics and Management of COVID-19 in Cancer Patients

Shahzar Khan, Hasnain Jan, Shah Faisal, Ayyaz Khan, Rashida Ilyas, Khadija Bibi, Sadeeq ur Rehman


COVID-19 is extremely lethal disease and almost 190 countries is suffering from the latest pandemic. The literature indicates that COVID-19 is more prevalent in patients with compromised immune systems. Patients with cancer are particularly vulnerable to COVID-19 because of immune compromised condition due to immunosuppressive therapy. Immunotherapy results in mixing or overlap of COVID-19 associated pneumonia and immune-related pneumonitis and thus makes the diagnosis process very confusing. On the other side in this pandemic, treating cancer patients in hospital will bring a lot of risk. There is still no strong evidence on the cancer-COVID-19 connection. Yet, in this pandemic, patients with cancer should be treated as special cases. Risk management is highly needed in the critical time of this pandemic. This review highlights the association between COVID-19 and cancer, also the strategy to minimize the risk of COVID-19 in cancer patients.


COVID-19, Cancer, Immunosuppressive therapy, Risk

Full Text:



Huang C et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020; 395(10223):497-506.

Zhu N et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 2020. doi: 10.1056/NEJMoa2001017

Jan H et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries, 2020. 8(2). doi: 10. 15190/d.2020.5

Baloch S et al. The Coronavirus Disease 2019 (COVID-19) Pandemic. The Tohoku Journal of Experimental Medicine, 2020. 250(4):271-278. doi. org/10. 1620/tjem.250.271

Bai, Y et al. Presumed asymptomatic carrier transmission of COVID-19. Jama, 2020. 323(14):1406-1407. doi:10.1001/jama.2020.2565

Tyrrell D and M Bynoe. Cultivation of viruses from a high proportion of patients with colds. Lancet, 1966.

Lillie PJ et al. Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission. Journal of Infection, 2020. 80(5):578-606.

Liang W et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology, 2020. 21(3):335-337.

Yu J et al. SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. medRxiv, 2020.

Xia Y et al. Risk of COVID-19 for patients with cancer. The Lancet Oncology, 2020. 21(4):180.

Picchianti DA et al. Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. International Journal of Molecular Sciences, 2020. 21(9):3330.

Smith JC and Sheltzer JM. Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2. bioRxiv, 2020.

Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Future Medicine. 2020.

Mehta P et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet, 2020. 395(10229):1033-1034.

Postow MA, Sidlow R, and Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 2018. 378(2):158-168. doi: 10.1056/NEJMra1703481

Russell CD, Millar JE, and Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet, 2020. 395(10223):473-475. doi: 10.1016/j.jtho.2020.02.025

Zhang H, Huang Y, and Xie C. The treatment and outcome of a lung cancer patient infected with SARS-CoV-2. Journal of Thoracic Oncology, 2020. doi: 10.1016/j.jtho.2020.02.025

Hwang DM et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern pathology, 2005. 18(1):1-10.

Franks TJ et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Human pathology, 2003. 34(8):743-748.

Tian S et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. Journal of Thoracic Oncology, 2020.

Bonomi L et al. A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab. Journal of Thoracic Oncology, 2020.

Wu Z and McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama, 2020. 323(13):1239-1242. doi:10.1001/jama.2020.2648

Cai H. Sex difference and smoking predisposition in patients with COVID-19. The Lancet Respiratory Medicine, 2020. 8(4):e20. 1016/S2213-2600(20)30117

Chen N et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020. 395(10223):507-513.

Beaver K et al. Comparing hospital and telephone follow‐up for patients treated for stage–I endometrial cancer (ENDCAT trial): a randomised, multicentre, non‐inferiority trial. BJOG: An International Journal of Obstetrics & Gynaecology, 2017. 124(1):150-160.

Frankland J et al. Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme. BMC cancer, 2019. 19(1):368.

Schmidt-Hansen M, Baldwin DR and Hasler E. What is the most effective follow-up model for lung cancer patients? A systematic review. Journal of Thoracic Oncology, 2012. 7(5):821-824.

Cusack M and Taylor C. A literature review of the potential of telephone follow‐up in colorectal cancer. Journal of Clinical Nursing, 2010. 19(17‐18):2394-2405.

Pignon JP et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy and oncology, 2009. 92(1):4-14.

Remuzzi A and Remuzzi G. COVID-19 and Italy: what next? The Lancet, 2020.

Goel AN et al. The impact of treatment package time on survival in surgically managed head and neck cancer in the United States. Oral oncology, 2019. 88:39-48.

Song S et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer, 2013. 119(2):325-331.

Mao L et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology, 2020. doi:10.1001/jamaneurol.2020.1127

Roder D et al. Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival. BMJ open, 2019. 9(9):e031421. doi: 10.1136/bmjopen-2019-031421

Kucejko RJ et al. How Soon Should Patients With Colon Cancer Undergo Definitive Resection? Diseases of the Colon & Rectum, 2020. 63(2): 172-182. doi: 10.1097/DCR.0000000000001525

Delisle M et al. The Association Between Wait Times for Colorectal Cancer Treatment and Health Care Costs: A Population-Based Analysis. Diseases of the Colon & Rectum, 2020. 63(2):160-171. doi: 10.1097/DCR.0000000000001517

Siegel RL, Miller KD and Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians, 2019. 69(1):7-34.

Mehta P et al. Correspondence COVID-19: consider cytokine storm syndromes and. Lancet, 2020. 6736(20):19-20. doi. org/10. 1016/S0140-6736(20)30628.

Shewan, L.G., A.J.S. Coats, and M. Henein. Authors’ Responsibilities and Ethical Publishing. in International Cardiovascular Forum Journal. 2018. DOI: 10.17987/icfj. v13i0. 525


Copyright (c) 2020 The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.